To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Injection of Botulinum toxin A provides pain relief for lateral epicondylitis

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
March 2014

Injection of Botulinum toxin A provides pain relief for lateral epicondylitis

Vol: 3| Issue: 3| Number:79| ISSN#: 2564-2537
Study Type:Meta-analysis/Systematic Review
OE Level Evidence:3
Journal Level of Evidence:N/A

Injection of Botulinum Toxin for Treatment of Chronic Lateral Epicondylitis: Systematic Review and Meta-Analysis

Semin Arthritis Rheum. 2011 Jun;40(6):532-8. doi: 10.1016/j.semarthrit.2010.07.002. Epub 2010 Sep 6.

Contributing Authors:
L Kalichman RR Bannuru M Severin W Harvey

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

This systematic review/meta-analyis utilized 10 studies (4 RCTs and 6 studies of varying quality) assessing the short term efficacy of botulinum toxin A injections into the forearm extensor muscles of patients with lateral epicondylitis. Meta-analysis utilizing the 4 included RCTs indicated that VAS pain at 4 weeks and 3 months post-intervention favoured botulinum toxin over saline solution. The r...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue